AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system (bipolar disorder for example). AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY.

AGY Therapeutics Inc. : A Great

Innovation for Advancing CNS

Treatments

AGY Therapeutics Inc. is on a mission to explore, develop, and commercialize therapeutics and transform the lives of patients. We are committed to pioneering breakthrough treatments for CNS disorders, and address the urgent medical needs. We aim to improve the lives of people who are suffering from brain-related medical conditions, such as bipolar disorder and other neurological diseases.

Introducing AGY Therapeutics Inc

AGY Therapeutics is a reputed South San Francisco-based biopharmaceutical company founded in 1998. We are dedicated to transforms the CNS Treatments through the cutting edge development and research. Our foundation lies in pathway mapping and functional gene discovery and allows you to identify the crucial proteins that drive CNS diseases. Our expert team also develops novel therapeutics, targets proteins, and reduces disease progression. This is how we help to improve patient medical results.

Who we are: Meet Our Founder

AGY Therapeutics Inc is founded by Karoly Nikolich, PhD. Dr Karoly is the visionary neuroscientist, president and chief scientific officer and have passion to understand the complexity of human brain functioning. His passion towards the neuroscience starts in childhood in Hungary, where he was empowered by Hungarian word "agy" (means brain).

Dr. Nikolich played a vital role to establish the Genentech's neuroscience research program in 1987. He also contributes to the field at Lynx Therapeutics. With his passion towards AGY, he push the boundaries of CNS research and lead a team committed to advance innovative therapies for neurological disorders.

Our Vision and Commitment

AGY Therapeutics, as the trusted biopharmaceutical company aims to revolutionize CNS treatment through scientific excellence and innovative research.

  • We believe in understanding the mechanisms of neurological and psychiatric disorders and develop targeted therapies to control disease progression and improve patients' results.
  • At AGY, we drive by single vision, to translate the groundbreaking research into transformative medicines.
  • In this way, we work to restore neurological health and improve the quality of life of millions of patients in the world.
  • Better Health, Bright Future: Our Unique Approach

    AGY Therapeutics Inc use the proprietary platform to explore the molecular mechanisms underlying psychiatric and neurological disorders. Our expertise in biotechnology, biopharma, genetics, and medical therapeutics allows us to

  • identify the main CNS drug targets
  • Develops the medical-stage therapies and advanced preclinical therapies
  • Converts groundbreaking research into life-changing drugs
  • Our Promise

    Our promise is to pursue groundbreaking scientific advancements and innovation to develop life-changing medicines for CNS diseases. Our professional team are committed to patient-centered innovation, excellence and integrity, and ensure that every therapy we create is driven by research and passion to improve patients life. With great dedication and an expert team, we bridge the gap between discovery and treatment and hope patients will recover from neurological conditions in a short period.

    Shaping the Future of CNS Treatments

    With a main focus on CNS therapies in development, we aim to drive innovation in neurological care and improve patient’s lives. Our commitment to medical excellence and patient-centric approach make us innovative in the next generation of CNS therapeutics. So, why you wait more? Join us to transform your journey of CNS healthcare. Explore AGY Therapeutics and discover the future of neuroscience-driven medicine.

    February 2, 2005

    AGY Therapeutics to Present at International Levitra Stroke Conference. >>

    Other News:

    July 20, 2004
    AGY Therapeutics Licenses Product Candidate from M's Science for Phase 2 Clinical Development. >>
    ©2004 AGY Therapeutics Inc. All rights reserved.